Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer

Journal of Clinical Oncology

Volumn 19, Issue 5, 2001, Pages 1444-1454

  Batist, G ^a   Ramakrishnan, G ^a   Rao, C S ^a   Chandrasekharan, A ^a   Gutheil, J ^a   Guthrie, T ^a   Shah, P ^a   Khojasteh, A ^a   Nair, M K ^a   Hoelzer, K ^a   Tkaczuk, K ^a   Youn Choi Park, ^a   Lee, L W ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; LIPOSOME; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; ENCAPSULATION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MULTICENTER STUDY; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE;

EID: 0035282073     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.5.1444     Document Type: Article

References (35)

1. Effect of anthracycline antibiotics on oxygen radical formation in rat heart
2. Adriamycin-induced free radical formation in the perfused rat heart: Implications for cardiotoxicity
3. Evaluation of free radical effects and catecholamine alterations in adriamycin cardiotoxicity
4. Adriamycin: The role of lipid peroxidation in cardiac toxicity and tumor response
5. Anthracycline cardiomyopathy monitored by morphologic changes
6. Adriamycin cardiotoxicity: A survey of 1273 patients
7. Risk factors for doxorubicin-induced congestive heart failure
8. Anthracycline cardiotoxicity
9. Liposomal doxorubicin
10. Preclinical toxicology study of liposome encapsulated doxorubicin (TLC D-99) given intraperitoneally to dogs
11. Preclinical toxicology study of liposome encapsulated doxorubicin (TLC D-99): Comparison with doxorubicin and empty liposomes in mice and dogs
12. Comparison of the cardiotoxic effects of liposomal doxorubicin (TLC D-99) versus free doxorubicin in beagle dogs
13. Antitumor activity of liposomal encapsulated doxorubicin in different murine tumor models: Implications for mechanisms of action
14. Liposomes: From the bench to the marketplace - Doxorubicin as an example
15. Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor
16. Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin
17. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography
18. Serial radionuclide assessment of doxorubicin cardiotoxicity in cancer patients with abnormal resting left ventricular performance
19. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer
20. Cardioprotection with dexrazoxane for doxorubicin containing therapy in advanced breast cancer
21. Adriamycin RDF (doxorubicin hydrochloride for injection, USP)
22. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood
23. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: The Pediatric Oncology Group experience
24. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy
25. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion
26. Epirubicin cardiotoxicity: An analysis of 469 patients with metastatic breast cancer
27. Doxil (doxorubicin HCI liposome injection)
28. Doxorubicin fluorescence in a human breast carcinoma (MX-1), after treatment with liposome-associated or free doxorubicin
29. High response rate and visceral organ targeting by liposomal doxorubicin (TLC D-99) in metastatic breast cancer
30. Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer
31. Herceptin (trastuzumab)
32. Paclitaxel and cardiotoxicity